264 related articles for article (PubMed ID: 9833910)
1. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.
Angulo P; Therneau TM; Jorgensen A; DeSotel CK; Egan KS; Dickson ER; Hay JE; Lindor KD
J Hepatol; 1998 Nov; 29(5):729-35. PubMed ID: 9833910
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
3. The metabolic bone disease of primary sclerosing cholangitis.
Hay JE; Lindor KD; Wiesner RH; Dickson ER; Krom RA; LaRusso NF
Hepatology; 1991 Aug; 14(2):257-61. PubMed ID: 1860683
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
[TBL] [Abstract][Full Text] [Related]
5. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Tung BY; Emond MJ; Haggitt RC; Bronner MP; Kimmey MB; Kowdley KV; Brentnall TA
Ann Intern Med; 2001 Jan; 134(2):89-95. PubMed ID: 11177311
[TBL] [Abstract][Full Text] [Related]
6. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
8. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
Stiehl A
Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
[TBL] [Abstract][Full Text] [Related]
10. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis.
Campbell MS; Lichtenstein GR; Rhim AD; Pazianas M; Faust T
Liver Int; 2005 Apr; 25(2):311-6. PubMed ID: 15780055
[TBL] [Abstract][Full Text] [Related]
11. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
12. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
14. Novel developments in IBD-related sclerosing cholangitis.
Ponsioen CY
Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S15-8. PubMed ID: 21640925
[TBL] [Abstract][Full Text] [Related]
15. Bile acids for primary sclerosing cholangitis.
Chen W; Gluud C
Cochrane Database Syst Rev; 2003; (2):CD003626. PubMed ID: 12804480
[TBL] [Abstract][Full Text] [Related]
16. [Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk].
MMW Fortschr Med; 2006 Jun; 148(24):42-3. PubMed ID: 16850808
[No Abstract] [Full Text] [Related]
17. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.
Stiehl A; Rudolph G; Sauer P; Benz C; Stremmel W; Walker S; Theilmann L
J Hepatol; 1997 Mar; 26(3):560-6. PubMed ID: 9075663
[TBL] [Abstract][Full Text] [Related]
19. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Yokoda RT; Carey EJ
Am J Gastroenterol; 2019 Oct; 114(10):1593-1605. PubMed ID: 31169523
[TBL] [Abstract][Full Text] [Related]
20. Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature.
Larsen EP; Bayat A; Vyberg M
Diagn Pathol; 2012 Aug; 7():100. PubMed ID: 22891962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
